Live30 webinars are thirty minute presentations designed to update you on the latest innovations, applications and data in a fast yet interactive format.
As part of the innate immune response, Natural Killer (NK) cells respond to anything they perceive as “non-self”, including malignant cells, making them a promising effector cell for adoptive immunotherapy of cancers. Unlike T-cells, NK cells provide an anticancer response in an antigen independent manner, allowing NK cells to be a potential “off the shelf” allogeneic therapeutic product. Thus, they have the potential to be safer, less expensive, and more effective than current engineered T-cell therapies. One of the key challenges faced by the cell and gene therapy industry is the ability to expand and process NK cells using regulation-compliant reagents and closed manufacturing systems. In this presentation, we will discuss how CTS™ NK-Xpander™ Medium and the CTS™ Rotea™ Counterflow Centrifugation System increase the ability to generate and process large numbers of functionally viable human NK cells, filling a need for translational researchers to bring NK adoptive cell therapies to the clinic.
CTS™ NK-Xpander™ Medium, a new NK cell culture medium developed to support feeder-free human NK cell expansion in vitro, expands functional primary human NK cells to clinically relevant levels in two to three weeks. NK cells cultured with CTS NK-Xpander Medium in a G-rex®, Xuri™ Cellbag or HyPerforma™ Bioreactor yields up to 6 billion functional NK cells within 3 weeks.
The Gibco™ CTS™ Rotea™ Counterflow Centrifugation System is a closed cell processing system developed for small-batch cell therapy manufacturing. Using the CTS™ Rotea™ system, Leukopaks were processed and human NK cells enriched by negative selection. Post expansion, the NK cells were loaded into the CTS™ Rotea™ system to form a stabilized bed for subsequent washing in CTS™ DPBS. Recovery was ~90% with high viability and maintenance of cellular phenotype and function.